Ibopamine (SK&F 100168) pharmacokinetics in relation to the timing of meals.
The effect of the timing of a standard meal relative to a single oral dose of 200 mg ibopamine, on the appearance of its pharmacologically active metabolite, epinine, in plasma was investigated in a randomised crossover study in 12 healthy volunteers. After a 12 h fast, ibopamine was administered either in the fasting state (no meal), or 1 h before, 0.5 h before, immediately after, 2 h after or 3 h after a standardised meal. Blood samples taken immediately before and at intervals for 3 h after dosing were analysed for free epinine. Maximum concentration (Cmax), time to Cmax(tmax), and area under the concentration-time curve (AUC) for free epinine in plasma were calculated. When compared with the fasting state, Cmax and AUC0-3h were significantly reduced when ibopamine was given immediately after or 2 h after a meal. AUC was also reduced for ibopamine given 0.5 h before a meal. tmax was significantly delayed when ibopamine was given immediately after, or 2 or 3 h after a meal. Thus, administration of ibopamine with or shortly after a meal reduced the rate and extent of appearance of free epinine in plasma. The clinical significance of reduced epinine levels on acute dosing in the presence of food is unknown.
D000328:Adult; D003846:Deoxyepinephrine / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism; D004298:Dopamine / Q000031:analogs & derivatives*; D005260:Female; D005502:Food; D006801:Humans; D007700:Kinetics; D008297:Male; D011897:Random Allocation
C023487:ibopamine; D003846:Deoxyepinephrine; D004298:Dopamine